These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 19441719

  • 1. [Therapeutic effect and pharmacokinetics of transdermal phenazepam preparation in patients with different anxiety disorders].
    Dorofeeva OA, Siuniakov SA, Zherdev VP, Kolyvanov GB, Litvin AA, Neznamov GG.
    Eksp Klin Farmakol; 2009; 72(2):6-10. PubMed ID: 19441719
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacokinetics and efficacy of phenazepam after transdermal and enteral administration in rats].
    Zherdev VP, Voronina TA, Garibova TL, Kolyvanov GB, Litvin AA, Sariev AK, Tokhmakhchi VN, Vasil'ev AE.
    Eksp Klin Farmakol; 2003; 66(1):50-3. PubMed ID: 12683082
    [Abstract] [Full Text] [Related]

  • 3. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam.
    Klein E.
    J Clin Psychiatry; 2002; 63 Suppl 14():27-33. PubMed ID: 12562116
    [Abstract] [Full Text] [Related]

  • 4. [Effect of phenazepam in various medicinal forms on psychophysical state of patients with anxiety disorders].
    Neznamov GG, Dorofeeva OA, Teleshova ES, Siuniakov SA, Mametova LÉ.
    Eksp Klin Farmakol; 2011; 74(5):6-12. PubMed ID: 21809691
    [Abstract] [Full Text] [Related]

  • 5. Biokinetics of transdermal therapeutic medicinal form of phenazepam.
    Golovenko NY, Kravchenko IA, Zin'kovskii VG, Andronati SA, Aleksandrova AI, Ovcharenko NV, Larionov VB.
    Bull Exp Biol Med; 2000 Dec; 130(12):1153-5. PubMed ID: 11276308
    [Abstract] [Full Text] [Related]

  • 6. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].
    Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014 Dec; 114(7):17-22. PubMed ID: 25176261
    [Abstract] [Full Text] [Related]

  • 7. Anxiety disorders. Part 2: Pharmacotherapy with benzodiazepines.
    Labelle A, Lapierre YD.
    Can Fam Physician; 1993 Oct; 39():2205-8; 2211-3. PubMed ID: 8106034
    [Abstract] [Full Text] [Related]

  • 8. [Experimental pharmacokinetics of phenazepam during transdermal administration of the therapeutic phenaperkuten system].
    Litvin AA.
    Eksp Klin Farmakol; 2004 Oct; 67(2):59-62. PubMed ID: 15188765
    [Abstract] [Full Text] [Related]

  • 9. Switching from benzodiazepines to buspirone using a tapered overlap method in generalized anxiety disorder.
    Arató M.
    J Clin Psychiatry; 2001 Aug; 62(8):657-8. PubMed ID: 11561943
    [No Abstract] [Full Text] [Related]

  • 10. [Clinical study of the selective anxiolytic agent afobazol].
    Neznamov GG, Siuniakov SA, Chumakov DV, Bochkarev VK, Seredenin SB.
    Eksp Klin Farmakol; 2001 Aug; 64(2):15-9. PubMed ID: 11548440
    [Abstract] [Full Text] [Related]

  • 11. [Update on benzodiazepines].
    Marino A, Costa R.
    Recenti Prog Med; 1992 May; 83(5):249-54. PubMed ID: 1359614
    [Abstract] [Full Text] [Related]

  • 12. The use of benzodiazepines in the aged patient: clinical and pharmacological considerations.
    Dailly E, Bourin M.
    Pak J Pharm Sci; 2008 Apr; 21(2):144-50. PubMed ID: 18390445
    [Abstract] [Full Text] [Related]

  • 13. [Excerpts from the clinical-pharmacologic and clinical studies of Grandaxin].
    Szegó J, Somogyi M, Papp E.
    Acta Pharm Hung; 1993 Mar; 63(2):91-8. PubMed ID: 8100114
    [Abstract] [Full Text] [Related]

  • 14. [Optimization of the treatment of anxiety disorders with selank].
    Medvedev VE, Tereshchenko ON, Kost NV, Ter-Israelyan AY, Gushanskaya EV, Chobanu IK, Sokolov OY, Myasoedov NF.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015 Mar; 115(6):33-40. PubMed ID: 26356395
    [Abstract] [Full Text] [Related]

  • 15. Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy.
    Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L.
    J Consult Clin Psychol; 2006 Oct; 74(5):908-19. PubMed ID: 17032095
    [Abstract] [Full Text] [Related]

  • 16. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents.
    Stevens JC, Pollack MH.
    J Clin Psychiatry; 2005 Oct; 66 Suppl 2():21-7. PubMed ID: 15762816
    [Abstract] [Full Text] [Related]

  • 17. Anxiety states and benzodiazepines.
    Tollefson G, Lesar T, Teubner-Rhodes D.
    Am Fam Physician; 1983 May; 27(5):151-8. PubMed ID: 6133442
    [Abstract] [Full Text] [Related]

  • 18. Attitudes toward benzodiazepines over the years.
    Rosenbaum JF.
    J Clin Psychiatry; 2005 May; 66 Suppl 2():4-8. PubMed ID: 15762813
    [Abstract] [Full Text] [Related]

  • 19. Physician Withdrawal Checklist (PWC-20).
    Rickels K, Garcia-Espana F, Mandos LA, Case GW.
    J Clin Psychopharmacol; 2008 Aug; 28(4):447-51. PubMed ID: 18626273
    [Abstract] [Full Text] [Related]

  • 20. Quazepam: a new hypnotic.
    Med Lett Drugs Ther; 1990 Apr 20; 32(816):39-40. PubMed ID: 1970112
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.